BioWorld

April 10, 2007

Sirion Series B Raises $45M For Phase III Ophthalmic Bid

Ophthalmics-targeted Sirion Therapeutics Inc. pulled down $45 million in a Series B financing to boost a pipeline led by ST-601, the Phase III emulsion acquired last year for inflamed eyes. (BioWorld Today) Read More

Senate Schedules Stem Cell Debate And Vote For Today

Alteon Raising $25M Privately, Expanding Rights To ALT-2074

Melior Grants Pfizer Access To Multiplexed In Vivo Platform

EPA Awards $111M In BioPharma Contracts

Appointments And Advancements

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...